The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?

Parenteral amphotericin B has been considered as first-line therapy in the treatment of systemic fungal and parasitic infections, however its use has been associated with a number of limitations including affordability, accessibility, and an array of systemic toxicities. Until very recently, it has...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Pharmaceutics
المؤلفون الرئيسيون: Grace Cuddihy, Ellen K. Wasan, Yunyun Di, Kishor M. Wasan
التنسيق: مقال
اللغة:الإنجليزية
منشور في: MDPI AG 2019-02-01
الموضوعات:
الوصول للمادة أونلاين:https://www.mdpi.com/1999-4923/11/3/99

مواد مشابهة